MabVax Therapeutics Holdings Inc
MabVax Therapeutics — Virtual Investor Conference (May 2018)
25 slides from MabVax Therapeutics's conference presentation, May 3, 2018
Slide 1: MabVax Therapeutics Virtual Investor Conference
\y/ MabVax therapeutics Virtual Investor Conference May 3, 2018 NASDAQ: MBVX ‘wirenabvatlae
Slide 2: Forward Looking Statements
Forward Looking Statements MabVax Therapeutics Holdings, Inc. (the “Company”) files annual, quarterly and other reports withthe Securities and Exchange ‘Commission (the “SEC") including its Annual Report on Form 10-K forthe year ended December 3, 2017 (the “Form 10") which was filed on April 2, 2018
Slide 3: Unique Human Antibody Discovery and Development Platform Resulting in Clinical Pipeline
Unique Human Antibody Discovery and Development Platform Resulting in Clinical Pipeline Clinical stage biotech focused on discovery and early development ‘of therapeutic and diagnostic antibody based products Products intended to treat particularly dificult cancers Experienced senior team and resour
Slide 4: Discovery Platform
i, DISCOVERY PLATFORM
Slide 5: Human Antibody (HuMab) Discovery Platform
Human Antibody (HuMab) Discovery Platform Proprietary Approach to the Discovery and Development of Novel Fully Human Antibodies for Therapeutic and Diagnostic Agents Focused Discovery Screening Optimized Therapy Fully human antibody ‘minimizes immunogenicity. Binding sequence reflects the patient's
Slide 6: Vi Se
Vi Se Program Discovery _Lead Op Pre-IND Phase 1 Phase 2 ‘HuMab-5B1 for Pancreatic Cancer and CA19-9 malignancies including Lung and Gl Cancers ‘Therapeutic (MVE-S873): + Chemo Fane Pacrestc cance Thepee Therapeutic (MVE-S873): Monotherapy > Radioimmunotherapy (RT) (MVE1075) Dass acridine cance Toe
Slide 7: HuMab-5B1 Preclinical Development Program
i, HuMab-5B1 PRECLINICAL DEVELOPMENT PROGRAM Scientific Rationale and Development Strategy
Slide 8: The 5B1 Target
! { The 5B1 Target cover 90% of pancreatic anda rge + Plays ey role in tumor proteraton and + Tapers the eptope onan portant serum tumor marie ened A199 + cA19 9 vaidted diagno test and onsiseed a valle adunctin the ‘dagnons and monitoring of treatment of Expressed in Cancer Because + Targets densel
Slide 9: Integrated & Efficient Development Strategy
Integrated & Efficient Development Strategy Mi Antibody-Based Therapeutic Agent to Treat Very Difficult to Treat ‘Cancers Such as Pancreatic, Small Cell Lung, Gastric and Colon ‘adlolmmanotherapy conjugate in Phase, ‘producing localized tror ellie 2 ef me) “oe Radioimmunotherapy (vr-1075) Exablihed
Slide 10: HuMab-5B1 Phase Programs
i, HuMab-5B1 PHASE 1 PROGRAMS MVT-5873 Therapeutic Antibody Establishes Safety and MTD 10
Slide 11: Single Agent Monotherapy Phase 1a Trial Data Demonstrates Anti-Cancer Effect
Single Agent Monotherapy Phase 1a Trial Data Demonstrates Anti- Cancer Effect + study conducted in tage 3 and 4 POAC patents who have H failed all other therapies and have progressive disease 1 + Maximum Tolerated Dose (MTO) established | + Identified subset (n=13 oF 41%) with 250% reduction in | ‘A
Slide 12: MVT-5873 Demonstrates Marked Efficacy in Combination with First Line Chemotherapy in PDAC
MVT-5873 Demonstrates Marked Efficacy in Combination with First Line Chemotherapy in PDAC All Patients Experience Measurable + Combination with Gem/nab in first line Meaningful Reduction in Tumor Size by RECIST treatment of naive POAC patients + Dosing at 0.125 mg/kg weekly is generally well tolerat
Slide 13: Adding MVT-5873 To Standard of Care Improves Outcomes
Adding MVT-5873 To Standard of Care Improves Outcomes - Full Data Readout Mid-Year Best Response SOC (Gem#Nab)! Compete Response Less than 1% Partial Response 23% Stable Disease 2% Progressive Disease 20% Could not be evaluated 30% BL — SA Disease Control Rate 50% 100% (cRsPRSD) + Early results from
Slide 14: HuMab-5B1 Imaging Phase Program
i, HuMab-5B1 IMAGING PHASE 1 PROGRAM MVT-2163 PET Imaging Agent Establishes Safety and Targeting Mechanism 1s
Slide 15: HuMab-5B1 PET Agent Specifically Targets CA19-9 Positive Tumors
HuMab-5B1 PET Agent Specifically Targets CA19-9 Positive Tumors - Can Significantly Aid Diagnosis and Surgery Assessment Focal radiotracer uptake above background was observed in primary tumors and metastases from day 2 and continuously increased through day 7 + Day 7 tumor SUV,,,, Were as high as 1
Slide 16: HuMab-5B1 RIT Phase Program
i, HuMab-5B1 RIT PHASE 1 PROGRAM MVT-1075 Radioimmunotherapy (RIT) 16
Slide 17: RIT (MVT-1075) Phase 1a Clinical Trial
\ { RIT (MVT-1075) Phase 1a Clinical Trial One Cycle of Treatment Day 1 * MVT-5873 Cold Dose # ~Ahours wait Day 15 * MVT-1075 Hot Dose Day 57 Safety monitoring visits throughout and dosimetry completed day 8 cohort expansion sod of MEST / MT 10 Objectives + Determine the MTO and safety profile of MV
Slide 18: Lu-DTPA-HuMab-5B1: SPECT/CT
77\y-DTPA-HuMab-SB1: SPECT/C First cohort demonstrated dosimetry and organ exposure as expected Accumulation of radiolabeled antibody seen on tumor Good correlation with diagnostic CT Manageable hematologic toxicities Accrual is ongoing and dose escalation planned Announcement of cohort results in f
Slide 19: Anti-Tn Preclinical Antibody Program
i, Anti-Tn PRECLINICAL ANTIBODY PROGRAM Discovery, Engineering, Testing 10
Slide 20: Fully human lead anti-Tn antibody identified and optimized
Mi * Fully human lead anti-Tn antibody identified and optimized Binds specifically to target Tn In-house engineering effort improved affinity 325K Does not bind closely related antigens, retains high specificity of parent Internalizes efficiently, may be suitable as targeting agent * Lead antibody u
Slide 21: i,
i, CORPORATE UPDATE
Slide 22: Corporate Partnering
Corporate Partnering + Current assets are subject of ongoing partnering discussions Public guidance is we ‘expect to close one or more transactions this quarter + Greenhill & Co. engaged as advisory bank to facilitate transactions + + Lead 581 antibody in ‘combination with first line therapy in panc
Slide 23: Financial Snapshot
ial Snapshot M Finan NASDAQ MBVX Share Price* $1.30 Market Cap* $11.65M 50-Day Average Volume* 111K Common Stock Outstanding 9.0m Preferred Stock (Common Equivalents) 6.1M + Sharpe lume make and shares oustanding ae af ot 208
Slide 24: Management and Board of Directors
Management Management and Board of Directors Board of Directors PESTeT é 2. David Hansen 4. David Hansen President, CEO and Chairman UTA Bastyr Seas President, CEO and Chairman Gregory Hanson, CMA, MOA AN! JetreyF. Eisenberg Chief Financial Officer Mast CEO XeneticBiociences; Former CEO Noven Pharma
Slide 25: MabVax Therapeutics
MabVa» therapeutics NASDAQ: MBVX ‘wirenabvatlae
MabVax Therapeutics Holdings — Virtual Investor Conference (May 2018) on 6ix